ArticleTransplant infectious disease : an official journal of the Transplantation Society
Risk Factors for Breakthrough Cytomegalovirus Infections While on Prophylaxis in Kidney and Pancreas Transplant Recipients.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBreakthrough cytomegalovirus (CMV) infection during antiviral prophylaxis may result in significant morbidity. The purpose of this study was to identify the incidence of breakthrough CMV infection and subsequent risk factors in kidney and pancreas transplant recipients on antiviral prophylaxis.
methodsThis single-center retrospective cohort study examined 408 adult kidney and/or pancreas transplant episodes from 2018 to 2021 that received CMV antiviral prophylaxis after transplant. Multivariable Cox regression analysis was utilized to explore the association between breakthrough infection and previously identified risk factors, such as delayed graft function (DGF) and rejection.
resultsBreakthrough CMV infection occurred in 125/408 (30.8%) of patients. The median time to detection was 30 days after transplant (IQR: 18-50). Those with breakthrough infection had higher incidence of DGF, longer cold ischemic time, and were more commonly deceased donor transplant recipients. Multivariable Cox regression analysis showed DGF was a significant risk factor for breakthrough infection with an HR of 1.68 (95% CI [1.15, 2.45], p < 0.01).
conclusionEnsuring appropriate dosing of prophylaxis in the setting of DGF may result in decreased risk of breakthrough CMV infection and further complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.